Allgenesis Biotherapeutics Inc. announced topline data from the company’s Phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor agonist formulated as an aqueous solution eye drop for the treatment of Dry Eye Disease.
Allgenesis Biotherapeutics Inc. announced topline data from the company’s Phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor agonist formulated as an aqueous solution eye drop for the treatment of Dry Eye Disease.